FTSE 100 news / Companies and sectors / AstraZeneca / 8 October 2026
AstraZeneca (AZN): news on Thursday 8 October 2026
+6.7 strongly positive
Coverage was mostly positive, centred on the new $1bn Massachusetts R&D centre, the Summit Therapeutics collaboration and analyst support from Jefferies, Citi and Berenberg ahead of third-quarter results. Share price moves were small and mixed.
What drove it
- analyst ratings ahead of Q3
- new R&D centre
- Summit Therapeutics deal
The 27 stories
- +9.2 Jefferies keeps 'buy' on AstraZeneca, sees 46% upside ahead of Q3 results with strong revenue and earnings forecast.
Jefferies keeps buy, sees large upside - +8.3 US bank expects AstraZeneca to beat third-quarter forecasts as path clears to key lung cancer data
Bank expects Q3 beat and key lung cancer data - +8.3 Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results
Jefferies maintains buy before quarterly results - +8.3 Citi raises target for AstraZeneca stock to GBp 18,600
Citi raises price target - +7.5 AstraZeneca PLC : Buy rating from Berenberg
Berenberg buy rating - +6.7 AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
Collaboration with Daiichi Sankyo and Summit - +6.7 AstraZeneca (LSE:AZN) Summit Therapeutics Investment Deepens Its Cancer Pipeline While FTSE 100 Trades Higher
Summit investment deepens cancer pipeline - +6.7 AstraZeneca opens new global strategic R&D centre in Massachusetts, US
Opens new global strategic R&D centre - +6.7 AstraZeneca (LSE:AZN) Opened A $1 Billion R&D Center In Kendall Square
Opened $1 billion R&D centre - +6.7 A Quick Look at Today's Ratings for AstraZeneca(AZN.US), With a Forecast Between $198.81 to $262.42
Analyst price targets well above current share price - +6.7 AstraZeneca targets weight-loss market with three new drugs, including a daily pill
New weight-loss drugs including daily pill - +6.7 AstraZeneca stock targets the weight loss market with three drugs
Targeting weight loss market with three drugs - +6.7 AstraZeneca's contentious Cancer drug clears India’s SEC review
Cancer drug cleared India's expert committee review - +5.8 Carterra and AstraZeneca team up to advance lab-in-the-loop AI drug discovery
New AI drug discovery collaboration involving AstraZeneca - +5.8 Inside AstraZeneca’s US$1bn Tech-Integrated R&D Centre
Coverage of $1bn tech-integrated R&D centre - +5.0 Summit Therapeutics Rises as Investors Continue to Digest AstraZeneca Deal
AstraZeneca deal with Summit drawing investor attention - +5.0 AstraZeneca, MGB deals add momentum to Greater Boston office recovery
New Boston office deal seen as positive expansion - +5.0 Summit Therapeutics Stock Has The Bull Case Changed After AstraZeneca Backing
AstraZeneca backing of Summit seen as supportive - +5.0 AstraZeneca Wins Bid To Limit Expert Testimony In Patent Infringement Dispute
Won bid to limit expert testimony in patent dispute - +5.0 Carterra Advances Lab-In-The-Loop Drug Discovery Through New Scientific Collaboration
Carterra collaboration on drug discovery - +5.0 AstraZeneca stock forecast: Breakout attempt eyes GBX12,282 resistance
Technical forecast sees breakout attempt - +4.2 AstraZeneca (LSE:AZN) Stock Looks Below Fair Value As Spending Rises
Valuation analysis says stock below fair value - +4.2 HOK and Pickard Chilton Design AstraZeneca R&D Center in Kendall Square
Design of new AstraZeneca R&D centre in Kendall Square - +4.2 Is FTSE 100 AstraZeneca (LSE:AZN) Rewriting Its Respiratory Story This Autumn?
Focus on respiratory portfolio progress - +3.3 AstraZeneca (LSE:AZN) Stock Looks Reasonable Based On Current Earnings
Stock looks reasonably valued on earnings - −1.7 Nordic stocks in North America - AstraZeneca fell 0.6%
Shares fell 0.6% in North American trading - +0.3 AstraZeneca stock gains 0.03 percent pre-market to EUR 143.08
Tiny pre-market share price move, essentially flat
AstraZeneca: every day · Pharma and healthcare on 8 October 2026 · FTSE 100 overview for the day